Medical Aesthetics Stock Surges 405% on Major Shareholder Move and Delisting Discussions

Venus Concept Inc. (VERO), a global leader in energy-based medical aesthetics technology, has become the center of significant market activity following a regulatory filing that revealed unexpected developments involving its largest stakeholder. The stock experienced a dramatic 405% jump in pre-market trading on Friday, driven by an amended 13D/A disclosure dated January 15, 2026.

Major Shareholder Consolidates Control

According to the regulatory filing, Madryn Asset Management has secured a dominant 91% ownership stake in the company, holding 18,763,125 shares. This substantial shareholding positions Madryn as the clear controlling force behind Venus Concept’s strategic direction and operational decisions.

Delisting Proposal Under Discussion

The filing indicates that on January 13, 2026, Madryn initiated board-level discussions proposing significant structural changes to Venus Concept. Most notably, the shareholder has expressed interest in exploring the potential delisting and deregistration of the company’s Common Stock from public markets. Additionally, Madryn outlined its preference for the company to pursue operational cost reduction initiatives, signaling a potential shift toward a private company structure.

Company Profile and Market Position

Venus Concept operates as a comprehensive medical aesthetics technology firm, providing innovative solutions across multiple treatment categories. The company’s technology portfolio encompasses energy-based devices (EBDs) and advanced robotic hair-restoration systems. Its product offerings address diverse aesthetic needs, including body contouring procedures, skin tightening treatments, facial rejuvenation solutions, resurfacing applications, and hair-removal innovations. These technologies are currently distributed across more than 60 countries worldwide, reflecting the company’s established international presence.

Stock Performance and Current Trading

Over the past twelve months, VERO has fluctuated between $1.39 and $14.5, reflecting the volatility characteristic of smaller-cap healthcare companies. At Friday’s pre-market open, the stock was trading at $7.25, representing the significant 405% surge that captured market attention. This dramatic move underscores investor reaction to the structural changes contemplated by the company’s dominant shareholder.

Disclaimer: The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.